- Benjamin R. Cowen, PhD, MBA
Chief Executive Officer
Dr. Cowen has 20 years experience working with private, early-stage biotechnology companies and public companies including, Shire and Merck, where he held a of number management positions and received recognition for leading high-performance teams and successfully completing key business development transactions. Dr. Cowen most recently served as the Vice President of Corporate Development at Milestone Pharmaceuticals, where he played a key role in a Series B financing and was responsible for business development and commercial activities. Dr. Cowen has also served on Atrin Pharmaceuticals’ Board of Directors since its inception in 2012. Dr. Cowen received his Ph.D. from University of Illinois at Urbana Champaign, his MBA from Carnegie Mellon University, his BA at Brandeis University and was an NIH Post-Doctoral Fellow at the Univ of Pennsylvania.
- Vincent J. O’Neill, M.D., B.Sc., M.R.C.P
Chief Medical Officer
Dr. Vincent J. O’Neill, a medical oncologist, joins ImmunoMet with 16 years of therapeutic and diagnostic product development experience, with senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics, where he led the design and management of Mirna’s Phase 1 clinical trial of MRX34, its lead product candidate and the first microRNA therapeutic in clinical development in cancer. Dr. O’Neill also served as Chief Medical Officer at Exosome Diagnostics, where he oversaw global product development and Medical Affairs. At both Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approval of Genentech’s Avastin® and Tarceva® oncology therapeutics. At GSK, he was clinical director of the signal transduction discovery unit and led the first IND application and clinical trial of MEK inhibitor MEKINIST®.
Dr. O’Neill received his M.D. and his B.Sc. in molecular pathology from the University of Glasgow. He has authored multiple peer-reviewed publications and conference presentations. Dr. O’Neill is also a member of the Royal College of Physicians.
- Allan L. Shaw
Chief Financial Officer
Allan L. Shaw currently serves as a director of VIVUS, Inc. Prior to joining ImmunoMet, Mr. Shaw was the Chief Financial Officer and Treasurer of Syndax Pharmaceuticals, Inc., a publicly listed clinical stage biopharmaceutical company. Mr. Shaw was Managing Director of Alvarez & Marsal LLC, a global professional services firm, and led their biopharmaceutical consulting practice from December 2011 to March 2015. He supported the firm on an ad hoc basis from March 2015 to October 2015. From 2009 to 2011. Mr. Shaw served as the Chief Financial Officer of NewLead Holdings LTD., a publicly traded global shipping company. From 2005 to 2009, he was the founder and Senior Managing Director of Shaw Strategic Capital LLC, an international financial advisory firm, focused on providing strategic financial counsel on a wide variety of issues such as general corporate finance, mergers and acquisitions, capital structuring, licensing and capital markets. From 2002 to 2004, Mr. Shaw was the Chief Financial Officer of Serono S.A., a publicly traded global biotechnology company, and from 1994 to 2001, he was the Chief Financial Officer at Viatel, Inc.
Mr. Shaw serves on the board of directors of Edith & Carl Marks JCH of Bensonhurst, a non-profit organization. He also served on the board of directors of Akari Therapeutics, Plc. from 2013 to 2016, the Central New York Biotech Accelerator (formerly Central New York—Biotech Research Center) from 2009 to 2013, NewLead Holdings LTD. from 2009 to 2011, Navios Maritime Holdings, Inc. from 2005 to 2010, Serono S.A. as an Executive Management Board Member from 2002 to 2004 and Viatel Inc. from 1996 to 2002.
Mr. Shaw received a B.S. from the State University of New York (Oswego College) and is a certified public accountant in the State of New York.
- Sanghee Yoo, Ph.D.
Vice President, Head of Biology
Prior to joining ImmunoMet, Dr. Yoo served as the Head of the New Drug Development Team at HanAll Biopharma, leading and managing drug development projects targeting cancer metabolism and fibrosis. She has more than 20 years of working experiences in cystic fibrosis, pain, and oncology and has shown successful leadership in projects ranging from target selection to clinical candidate nomination in several biotech companies including ProQR (Netherlands), Vertex Pharmaceuticals, Aurora Biosciences and Arcaris. Sanghee obtained her Ph.D. in biochemistry from the University of Utah, Salt Lake City, for work on protein-protein interactions between human cyclophilin A and HIV-1 capsid.
- Dr. Filip Janku, MD, PhD.
Clinical Consultant (Part time)
Dr. Janku is an Assistant Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center where he has been leading clinical trials for six years. He has been the principal investigator for numerous phase I protocols, most of which involve new developmental therapeutics with an emphasis on novel biologic and targeted molecules for the treatment of patients with various types of cancer. Dr. Janku has published over 148 articles in highly-respected, peer-reviewed journals. Dr. Janku's academic research interests focus on poof-of-concept clinical trials that possess a pivotal correlative component especially those involving oncogenic mutations by next generation sequencing, PI3K/AKT/mTOR pathway and Autophagy targets and OXPHOS inhibition pathway. He received MD/PhD from Charles University, Prague, Czech Republic and did a Clinical Research Fellowship at Investigational Cancer Therapeutics, the University of Texas, MD Anderson Cancer Center.
- Anthony A. Hörning
Business Advisor (Part time)
In 2014, Anthony A. Hörning founded Strategic Transactions Advisory AG (Basel, Switzerland) and since 2015, has been a Senior Advisor at Vantage Partners LLP (Boston, USA).
As Head of Alliance Management, he was in charge of the preparation, launch and ongoing implementation, as well as of all renegotiations, of Novartis Pharma global alliances and created a widely recognized alliance skills training program. He served for many years as a member of the board of the “Association of Strategic Alliance Professionals“. Prior to his career in Business Development & Licensing, Mr. Hörning was CFO of Novartis in Brazil and Head of Investor Relations & Capital Markets for the former Sandoz AG in Switzerland. He gained his initial training in international capital markets as a Vice-President with JPMorgan. He holds a Masters Degree in Business Administration from the University of Zürich.
Copyright © ImmunoMet. All rights reserved.